How can cobalamin injections be spaced in long-term therapy for inborn errors of vitamin B(12) absorption?

Abstract

Inborn errors of cobalamin (Cbl, vitamin B(12)) absorption include hereditary intrinsic factor deficiency (HIFD) and Imerslund-Gräsbeck disease (IGD). HIFD is secondary to mutations in the HIF gene while IGD is due to mutations in one of the 2 subunits of the intrinsic factor receptor that is cubilin (CUBN) or amnionless (AMN). These disorders lead to intracellular Cbl depletion which in turn causes megaloblastic bone marrow failure, accumulation of homocysteine and methylmalonic acid (MMA), and methionine depletion. The clinical presentation reflects Cbl deficiency, with gastrointestinal symptoms, pancytopenia, and megaloblastic anemia. Mixed proteinuria, when it is present is strongly suggestive of IGD. Accurate diagnosis is always an emergency because early detection and treatment with life-long parenteral pharmacological doses of hydroxocobalamin are life saving and prevent further deterioration. However, the optimal frequency for cobalamin injections as a maintenance therapy is poorly reported. In order to evaluate the optimal maintenance schedule of cobalamin injections, we retrospectively collected clinical, biological, molecular and treatment data on 7 patients affected with congenital Cbl malabsorption. Unlike previous recommendations, we showed that a maintenance dosage of 1 mg cobalamin twice a year was enough to ensure a normal clinical status and keep the hematological and metabolic parameters in the normal range. These data suggest that patients affected with inborn errors of cobalamin absorption may be safely long-term treated with cobalamin injections every 6 months with careful follow-up of hematological and metabolic parameters. This maintenance regime is beneficial because the patients' quality of life improves.

• Authors: Amina Boina Abdallah, Hélène Ogier de Baulny, Renata Kozyraki, Sandrine Passemard, Odile Fenneteau, Sophie Lebon, Odile Rigal, Bettina Mesples, Karima Yacouben, Stéphane Giraudier, Jean-François Benoist, Manuel Schiff
• Journal: Molecular genetics and metabolism (Mol Genet Metab) Vol. 107 Issue 1-2 Pg. 66-71 (Sep 2012) ISSN: 1096-7206 [Electronic] United States
• PMID: 22854512 (Publication Type: Journal Article)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• AMN protein, human
• Membrane Proteins
• Proteins
• Vitamin B 12

Topics

• Anemia, Megaloblastic
• Child
• Child, Preschool
• Female
• Genotype
• Humans
• Infant
• Injections
• Malabsorption Syndromes (diagnosis, drug therapy)
• Male
• Membrane Proteins
• Mutation
• Proteins (genetics)
• Proteinuria (diagnosis, drug therapy)
• Treatment Outcome
• Vitamin B 12 (administration & dosage, therapeutic use)
• Vitamin B 12 Deficiency (diagnosis, drug therapy)